Results of a clinical trial do not support the use of daily low-dose, extended-release morphine to relieve severe chronic breathlessness in people with COPD. The
Despite questionable efficacy and likelihood of producing a euphoric state, opioid analgesics (OAs) were prescribed concurrently with gabapentin (OACGs) with increasing frequency between 2006 and
The FDA yesterday issued Safety and Effectiveness of Certain Naloxone Hydrochloride Drug Products for Nonprescription Use, a document that may help facilitate the development and approval
Updated and expanded recommendations for clinicians providing pain care for adult outpatients with short- and long-term pain were released yesterday by the CDC. Published in
Whether opioids provide an acceptable risk–benefit balance when used for musculoskeletal pain at discharge from the emergency department (ED) is uncertain, conclude authors of a
Management of opioid use disorder (OUD) should be transformed through universal treatment with medications such as methadone, buprenorphine, and naltrexone, conclude authors of a Perspective
On days when oxycodone was administered, paroxetine significantly reduced the ventilatory response to hypercapnia in a study of 25 healthy participants. Quetiapine did not have
Long-term risks and benefits of opioid dose changes should be considered by clinicians and patients, authors conclude, based on a retrospective cohort study showing both
Compared with standard opioid prescribing in 193 patients after arthroscopic knee or shoulder surgery, a multimodal opioid-sparing postoperative pain management protocol significantly reduced postoperative opioid
“FDA Continues Important Work on Substance Use and Overdose Prevention Efforts” reviews the 7 recommendations made to FDA by the National Academies for Science, Engineering,